Non-toxic to non-cancerous cells, Disulfiram acts on cancer cells in a number of ways and is now undergoing further study.

And although there have been no well-defined studies regarding brain cancer and Disulfiram to date, it is viewed by researchers as one of the top potential off-label medications for cancer treatment.

  • Resources
  • Active Clinical Trials (4)
  • Studies

A write up on the resurgence Disulfiram is experiencing as a cancer drug from Nature Magazine: 


Title: Disulfiram in Recurrent Glioblastoma

Link: https://clinicaltrials.gov/ct2/show/NCT02678975

Inclusion criteria: Those experiencing Recurrence or Progression

Contact: Asgeir S Jakola, MD, PhD asgeir.jakola@vgregion.se


  • Cancer Clinic, St.Olavs University Hospital

Trondheim, Norway

Contact: Tora S Solheim, MD, PhD

Principal Investigator: Tora S Solheim, MD, PhD

  • Dept. of Oncology, Sahlgrenska University Hospital

Gothenburg, Sweden

Contact: Katja Werlenius, MD

Principal Investigator: Katja Werlenius, MD

  • Ryhov County Hospital

Jönköping, Sweden

Contact: Michael Strandéus, MD

Principal Investigator: Michael Strandéus, MD

  • Linköping University Hospital

Linkoping, Sweden

Contact: Munila Mudaisi, MD

Principal Investigator: Munila Mudaisi, MD

  • Lund University Hospital

Lund, Sweden

Contact: Sara Kinhult, MD, PhD

Principal Investigator: Sara Kinhult, MD, PhD

  • Karolinska University Hospital

Stockholm, Sweden

Contact: Sofia Hylin, MD

Principal Investigator: Sofia Hylin, MD

  • Uppsala University Hospital

Uppsala, Sweden

Contact: Magnus Lindskog, MD, PhD

Principal Investigator: Magnus Lindskog, MD, PHD

  • Örebro University Hospital

Örebro, Sweden

Contact: David Löfgren, MD

Principal Investigator: David Löfgren, MD

Treatment Protocol: Patients will be separated into one of two groups - one treatment group that will receive chemotherapy plus Disulfiram and Copper or a control group which will only receive chemotherapy.



Title: Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Link: https://clinicaltrials.gov/ct2/show/NCT02715609

Inclusion criteria: Newly diagnosed


  • Washington University School of Medicine Recruiting

Saint Louis, Missouri, United States, 63110

Contact: Jiayi Huang, M.D.    314-362-8516    jiayi.huang@wustl.edu

Principal Investigator: Jiayi Huang, M.D.

Sub-Investigator: Albert Kim, M.D., Ph.D.

Sub-Investigator: Jian Campian, M.D.

Sub-Investigator: Christina Tsien, M.D.

Sub-Investigator: Kareem Azab, Ph.D.

Sub-Investigator: Michael Chicoine, M.D.

Sub-Investigator: Keith Rich, M.D.

Sub-Investigator: Eric Leuthardt, M.D.

Sub-Investigator: Joshua Dowling, M.D.

Sub-Investigator: Gavin Dunn, M.D.

Sub-Investigator: George Ansstas, M.D.

Sub-Investigator: H. Michael Gach, Ph.D.

Sub-Investigator: Milan Chheda, M.D.

Sub-Investigator: Tanner Johanns, M.D., Ph.D.

Sub-Investigator: Gregory Zipfel, M.D.

Sub-Investigator: Joseph Ippolito, M.D., Ph.D.

Treatment Protocol: Patients will take Disulfiram and Copper in conjunction with the standard Chemotherapy and Radiation protocol.



Title: Bioavailability of Disulfiram and Metformin in Glioblastomas (INSIDE)

Link: https://clinicaltrials.gov/ct2/show/NCT03151772

Inclusion criteria: Newly diagnosed, Surgery Intended


  • Sahlgrenska University Hospital

Göteborg, Sweden

Contact: Louise Carstam, MD     46313421000     louise.carstam@vgregion.se

Contact: Asgeir S Jakola, MD, PhD     46313421000     asgeir.jakola@vgregion.se 

Treatment Protocol: Patients will take either Disulfiram or Metformin pre-operatively in order to determine whether either drug reaches the intended target (the tumor).



Title: Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme

Link: https://clinicaltrials.gov/ct2/show/NCT03363659

Inclusion Criteria: Newly Diagnosed, Unmethylated MGMT


  • Aurora Health Care, Aurora St. Luke's Medical Center

Milwaukee, Wisconsin, United States, 53215

Contact: Lynda Yanny    414-649-6685    lynda.yanny@aurora.org

Sub-Investigator: Richard A Rovin, MD

Sub-Investigator: Asad Khan, MD

Sub-Investigator: Amin Kassam, MD

Sub-Investigator: Santhi Konduri, PhD

Principal Investigator: Asadullah Khan, MD

Treatment Protocol: Patients will take Disulfiram and Copper in conjunction with the standard Chemotherapy and Radiation protocol.

Title: Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma

Link: https://pubmed.ncbi.nlm.nih.gov/27006494/

Summary: In this study, scientists explored the effects of Disulfiram and Copper against cancer cell lines and mice with implanted glioblastoma cells.

Key takeaways:

  • It inhibited cancer growth in a number of ways
  • It worked synergistically with chemotherapy
  • The authors recommend using it in both newly diagnosed and recurrent disease

The Latest on Disulfiram

Questions About Taking Disulfiram?
We're Here to Help